Combination therapy using nanomaterials and stem cells to treat spinal cord injuries
Yükleniyor...
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Elsevier Science
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
As a part of the central nervous system, the spinal cord (SC) provides most of the communications between the brain and other parts of the body. Any damage to SC interrupts this communication, leading to serious problems, which may remain for the rest of their life. Due to its significant impact on patients’ quality of life and its exorbitant medical costs, SC injury (SCI) is known as one of the most challengeable diseases in the world. Thus, it is critical to introduce highly translatable therapeutic platforms for SCI treatment. So far, different strategies have been introduced, among which utilizing various types of stem cells is one of the most interesting ones. The capability of stem cells to differentiate into several types of cell lines makes them promising candidates for the regeneration of injured tissues. One of the other interesting and novel strategies for SCI treatment is the appli- cation of nanomaterials, which could appear as a carrier for therapeutic agents or as a platform for culturing the cells. Combining these two approaches, stem cells and nanomaterials, could provide promising therapeutic strategies for SCI management. Accordingly, in this review we have summarized some of the recent advance- ments in which the applications of different types of stem cells and nanomaterials, alone and in combination forms, were evaluated for SCI treatment.
Açıklama
Anahtar Kelimeler
Stem Cell Therapy, Nanomaterials, Neuron, Regenerative Medicine, Spinal Cord Injury
Kaynak
European Journal of Pharmaceutics and Biopharmaceutics
WoS Q Değeri
Q1
Scopus Q Değeri
Q1
Cilt
177
Sayı
Künye
Zarepour A, Bal Öztürk A, Koyuncu Irmak D, Yaşayan G, Gökmen A, Karaöz E, Zarepour A, Zarrabi A, Mostafavi E. Combination Therapy Using Nanomaterials and Stem Cells to Treat Spinal Cord Injuries. Eur J Pharm Biopharm. 2022 Jul 15:S0939-6411(22)00142-4. doi: 10.1016/j.ejpb.2022.07.004. Epub ahead of print. PMIDV.
